BofA lowered the firm’s price target on Ultragenyx (RARE) to $74 from $79 and keeps a Buy rating on the shares. The firm adjusted targets among its small-to-mid cap biotech coverage as part of a Q3 earnings preview for the group.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- Ultragenyx placed on ‘Positive Catalyst Watch’ at JPMorgan
- Ultragenyx appoints Eric Olson Chief Business Officer
- Ultragenyx Pharmaceutical: Promising Phase 3 Results for DTX401 Reinforce Buy Rating
- Ultragenyx Pharmaceuticals: Strong Buy Rating Backed by Promising Osteogenesis Imperfecta Program and Strategic Developments
- Ultragenyx’s DTX401: Promising Phase 3 Results and Commercial Viability Support Buy Rating